Prism medico & pharmacy Limited has issued a regulatory clarification to stock exchanges regarding significant movement in its security price, attributing the fluctuations to market-driven speculation rather than any undisclosed material information.

Regulatory Disclosure Details

The company submitted its clarification on February 27, 2026, to both BSE Limited and Metropolitan Stock Exchange of India Limited (MSEI) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was made in response to exchange queries about recent price movements in the company's securities.

Management's Position on Price Movement

The company management emphasized that all material information bearing on operations and performance has been regularly disclosed to stock exchanges in a timely and accurate manner. The disclosure confirms compliance with corporate governance principles outlined in Regulation 4 of SEBI regulations and related circulars.

According to the company's statement, the price movement is purely attributed to:

• Market conditions and market-driven factors
• Speculative trading activities
• Factors beyond management control

Key Compliance Confirmations

The company provided several important confirmations in its regulatory filing:

Ongoing Regulatory Commitment

Prism Medico and Pharmacy Limited reiterated its commitment to maintaining transparency with stock exchanges and investors. The company confirmed it will continue to inform exchanges about any price-sensitive information as mandated under SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

The clarification was signed by Davender Singh, Director of the company (DIN: 09447213), emphasizing the management's direct involvement in ensuring regulatory compliance and transparent communication with stakeholders.

Prism Medico and Pharmacy Limited has submitted the scrutinizer's report for its Extraordinary General Meeting held on March 20, 2026, revealing overwhelming shareholder support with 99.98% approval for both special business resolutions. The company formally communicated the voting outcomes to BSE Limited and Metropolitan Stock Exchange of India Limited on March 24, 2026, completing the regulatory compliance process under Section 108 of the Companies Act, 2013.

EGM Proceedings and Shareholder Participation

The company's EGM was successfully conducted on March 20, 2026, at 01:00 P.M. through Video Conferencing/Other Audio Visual Means, chaired by Mrs. Sakshi Laller, Wholetime Director. The meeting concluded at 01:17 P.M. after addressing key corporate governance matters under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Voting Results and Scrutinizer's Report

M/s. M.R. Chechi & Associates, Practicing Company Secretaries from Chandigarh, served as scrutinizers for the e-voting process. CS Mast Ram Chechi (M. No.: 3823/C.P. No.: 2906) prepared the consolidated scrutinizer's report dated March 24, 2026, revealing exceptional shareholder consensus.

E-Voting Process and Participation

The company partnered with National Securities Depositories Limited (NSDL) to provide comprehensive voting facilities through their platform at www.evoting.nsdl.com . Remote e-voting commenced at 9:00 A.M. on March 17, 2026, and concluded at 5:00 P.M. on March 19, 2026. A total of 43 voters participated in the consolidated voting process across both remote e-voting and live e-voting during the meeting.

Regulatory Compliance and Communication

Director Davender Singh (DIN: 09447213) formally submitted the scrutinizer's report to both stock exchanges on March 24, 2026. The electronic voting details were downloaded from the NSDL Portal and votes were unblocked at 02:09 P.M. on March 20, 2026, after the EGM conclusion, in the presence of two independent witnesses - Tanish and Sparsh.

Preferential Issue Utilization Plan

With the approval of the preferential issue resolution, the company can now proceed with its comprehensive utilization plan for ₹25.00 crore:

The successful completion of the EGM and overwhelming shareholder approval enables Prism Medico to proceed with its pharmaceutical manufacturing expansion and corporate restructuring initiatives from its registered office at Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173030.